scorecardresearch
Saturday, April 27, 2024
TopicBharat Biotech

Topic: Bharat Biotech

Study shows Covaxin booster dose neutralises both Omicron, Delta variants: Bharat Biotech

Bharat Biotech said a study at Emory University demonstrated that people who got a Covaxin booster, 6 months after the two doses, witnessed neutralising of the two Covid variants.

Covaxin booster increases antibody levels by 19-97 fold against Covid variants: Phase 2 results

Study, which is yet to be peer-reviewed, was published on preprint portal medRxiv Saturday. It was conducted by Bharat Biotech and ICMR, which co-developed the vaccine.

Covaxin demonstrates robust safety and immunogenicity in 2-18-year-old volunteers, study says

The data was submitted to the Central Drugs Standard Control Organisation during October 2021 and received emergency use nod for children aged 12-18 from DCGI recently.

Covaxin was 50% effective among health workers in 2nd wave, real-world study from AIIMS shows

Study published in Lancet Infectious Diseases journal assessed 2,714 hospital workers from AIIMS New Delhi, who were most exposed to Covid and were primarily offered Covaxin.

Good news for kids: Expert panel gives Covaxin emergency approval for 2-18-year-olds

The phase 2/3 clinical trials for Covaxin for children were completed last month. The SEC will now send its recommendations to DCGI.

SII, Bharat Biotech get nod to export 10 lakh Covid vaccine doses under ‘Vaccine Maitri’

Ten lakh doses of Covaxin would be sent to Iran and 10 lakh doses of Covishield will be exported each to Myanmar, Nepal & Bangladesh under the ‘Vaccine Maitri’ programme in October.

NCB’s job is narcotics control, not headline mongering

ThePrint view on the most important issues, instantly.

Bharat Biotech vaccine for drug-resistant typhoid found safe, effective for children under 12 

The typhoid fever, caused by H58 Salmonella Typhi, a type of bacteria that has become resistant to multiple drugs, is an increasing public health threat in sub-Saharan Africa.

Bharat Biotech’s Ankleshwar plant, manufacturer of rabies vaccine, rolls out 1st batch of Covaxin

Health Minister Mansukh Mandaviya released the first commercial batch of Covaxin from the Gujarat plant Sunday, said it had the capacity to produce more than 1 crore doses per month.

Bharat Biotech, IVI announce phase 2/3 clinical trial of Chikungunya vaccine in Costa Rica

Trials for the vaccine, which International Vaccine Institute is developing in partnership with Bharat Biotech, are also expected to begin in Panama and Colombia by September.

On Camera

Indira, Manmohan, Modi, all raised income inequality. Until Hindu fears took the driving seat

The issue of inequality has assumed the blazing limelight at a time when inequality in India is said to be higher than it was in the British Raj. It's a ripe situation for half-truths and incendiary statements.

Foreign policy resonating among more Indians in 2nd & 3rd tier towns of India, says EAM Jaishankar

Speaking at launch of economist Surjit Bhalla’s book, S Jaishankar also highlights Gen Z’s engagement with ‘reel culture’, which has 'promoted awareness, created interest in many subjects'.

Germany removes restrictions, India can now buy small arms from its firms

Germany’s erstwhile Christian Democratic Union govt, led by Angela Merkel, prevented sale of small arms to police forces in states they perceived had ‘bad human rights record’.

Frontrunner is letting challenger define this poll campaign. Modi still hasn’t found a central theme

A theme has not yet emerged for BJP & people see lack of a contest, which makes it unexciting. For all these reasons, 2024 is turning out to be an unexpectedly theme-less election.